Dr. Yutaka Matsuda earned his first Ph.D. from Keio University in 2014. Before completing his doctorate, he began his scientific career at Ajinomoto Co., Inc. as a researcher in 2013. He transitioned to Ajinomoto Bio-Pharma Services in San Diego in 2018, focusing on antibody-drug conjugate (ADC) research. He earned a second Ph.D. from Tokyo University of Pharmacy and Life Sciences in 2021. The following year, he became the ADC project manager at Ajinomoto Bio-Pharma Services, San Diego. Dr. Matsuda now serves as the Director of Antibody-Drug Conjugate Chemistry at Exelixis Inc. He is deeply interested in ADC technology, especially in areas like payload-linker design, novel conjugation technology, process development, and analytical methods. Over the last decade, he has co-authored more than 50 publications, patents, and book chapters in the fields of medicine, synthetic chemistry, and ADCs. His work has garnered over 500 citations, boasting an h-index of 15.
Also see Dr Matsuda’s ADC Directory Profile.
